Table 4.

Controlled paracetamol consumption in other chronic liver diseases

Study	Liver disease	Paracetamol	Control	Duration	Result
Benson et al. 15	ALD (n = 6), Laennec's cirrhosis (n = 4), post‐necrotic cirrhosis (n = 1), chronic active hepatitis (n = 6), chronic persistent hepatitis (n = 4), primary biliary cirrhosis (n = 2) and unspecified cirrhosis (n = 1)	1 g four times daily (n = 20)	Placebo (n = 20)	13 day crossover (13 days paracetamol, 13 days placebo)	No significant change in bilirubin, ALP, AST or ALT
Dargère et al. 112	Chronic HCV	1 g three times daily (n = 17)	Placebo (n = 17)	7 days (additional 3 days monitoring)	No change in ALT or viral load
Dart et al. 107	Alcoholics with HCV	1 g four times daily (n = 24)	Placebo (n = 26)	5 days (additional 2 days monitoring)	No significant change in ALT, AST, INR or bilirubin